智通财经APP讯，中关村(000931.SZ)发布公告，公司下属公司山东华素制药有限公司于近日收到国家药品监督管理局核准签发的BDB片《药物临床试验批准通知书》。该药品用于治疗原发性高血压，为含有已知活性成分的新复方制剂，在境内外均未上市。其单方已在临床实践中展现了有效性和安全性，且联合使用为临床指南推荐。
智通财经APP讯，中关村(000931.SZ)发布公告，公司下属公司山东华素制药有限公司于近日收到国家药品监督管理局核准签发的BDB片《药物临床试验批准通知书》。该药品用于治疗原发性高血压，为含有已知活性成分的新复方制剂，在境内外均未上市。其单方已在临床实践中展现了有效性和安全性，且联合使用为临床指南推荐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.